Citation

BibTex format

@article{Sawicki:2022:10.1016/j.jcf.2022.02.003,
author = {Sawicki, GS and Chilvers, M and McNamara, J and Naehrlich, L and Saunders, C and Sermet-Gaudelus, I and Wainwright, CE and Ahluwalia, N and Campbell, D and Harris, RS and Paz-Diaz, H and Shih, JL and Davies, JC},
doi = {10.1016/j.jcf.2022.02.003},
journal = {JOURNAL OF CYSTIC FIBROSIS},
pages = {675--683},
title = {A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for <i>F508del</i> or heterozygous for <i>F508del</i> and a residual function <i>CFTR</i> variant},
url = {http://dx.doi.org/10.1016/j.jcf.2022.02.003},
volume = {21},
year = {2022}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AU - Sawicki,GS
AU - Chilvers,M
AU - McNamara,J
AU - Naehrlich,L
AU - Saunders,C
AU - Sermet-Gaudelus,I
AU - Wainwright,CE
AU - Ahluwalia,N
AU - Campbell,D
AU - Harris,RS
AU - Paz-Diaz,H
AU - Shih,JL
AU - Davies,JC
DO - 10.1016/j.jcf.2022.02.003
EP - 683
PY - 2022///
SN - 1569-1993
SP - 675
TI - A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for <i>F508del</i> or heterozygous for <i>F508del</i> and a residual function <i>CFTR</i> variant
T2 - JOURNAL OF CYSTIC FIBROSIS
UR - http://dx.doi.org/10.1016/j.jcf.2022.02.003
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000855309100024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
VL - 21
ER -